FDA Approves Updated Label for UNLOXCYT Based on Long-Term Data Showing Improved Outcomes in Advanced Cutaneous Squamous Cell Carcinoma
核心洞察
The FDA approved an updated label for UNLOXCYT (搜索) (cosibelimab-ipdl (搜索)) incorporating long-term follow-up data from the pivotal CK-301-101 trial showing improved objective response rates in advanced cutaneous squamous cell carcinoma (搜索).
At least 50% of patients achieved objective response in the 109-patient study, with median duration of response not reached in either metastatic or locally advanced cohorts at time of analysis.
UNLOXCYT (搜索) represents the first and only PD-L1 (搜索) immune checkpoint inhibitor approved for advanced CSCC, offering a unique mechanism that spares PD-L2 (搜索) and engages both adaptive and innate immune systems.
The U.S. Food and Drug Administration has approved an updated label for UNLOXCYT (搜索)™ (cosibelimab-ipdl (搜索)) based on long-term follow-up data demonstrating improved clinical outcomes in patients with advanced cutaneous squamous cell carcinoma (搜索) (aCSCC). Sun Pharmaceutical Industries Limited announced the approval on November 25, 2025, marking a significant milestone for the first and only PD-L1 (搜索) immune checkpoint inhibitor approved for this indication.
Enhanced Efficacy Data from Pivotal Trial
The updated label incorporates long-term follow-up data from the pivotal CK-301-101 trial, a multicenter, multicohort, open-label study of 109 patients with metastatic CSCC (搜索) (mCSCC) or locally advanced CSCC (搜索) (laCSCC) who are not candidates for curative surgery or curative radiation. The study included 78 patients with mCSCC and 31 patients with laCSCC.
The long-term analysis demonstrated improvement in the primary endpoint, objective response rate (ORR), with at least 50% of patients achieving objective response in both cohorts. This represents an increase from the primary analysis, with more complete responses observed compared to earlier data. Additionally, 14% of mCSCC patients and 32% of laCSCC patients achieved stable disease.
The median duration of response, a secondary endpoint, showed remarkable durability with longer follow-up. At the time of analysis, the median duration of response had not been reached in either the mCSCC or laCSCC cohorts, highlighting the sustained clinical benefit observed with UNLOXCYT (搜索) treatment.
Rapid Response Characteristics
Clinical trial participants demonstrated rapid response to treatment, with median time to response of 1.9 months (range: 1.6-16.9) in the mCSCC cohort and 3.6 months (range: 1.7-10.1) in the laCSCC cohort. This rapid onset of action represents an important clinical advantage for patients with advanced disease.
Maintained Safety Profile
The safety profile of UNLOXCYT (搜索) remained unchanged with the label update. In the CK-301-101 pivotal trial, the most common adverse reactions (≥10%) were fatigue, musculoskeletal pain, rash, diarrhea, hypothyroidism, constipation, nausea, headache, pruritus, edema, localized infection, and urinary tract infection.
Immune-mediated adverse reactions (imARs) occurred in 53 patients (24%) with a low incidence of high-grade events. Only two patients (0.9%) experienced high-grade imARs, both Grade 3 dermatologic reactions. Notably, there were no treatment-related deaths in the study.
Unique Mechanism of Action
UNLOXCYT (搜索) represents an evolution in checkpoint inhibition through its distinctive mechanism of action. The drug restores the adaptive immune response by inhibiting the binding of PD-L1 (搜索) with PD-1 (搜索) on T cells and B7.1 on antigen-presenting cells. Additionally, UNLOXCYT engages the innate immune system through an active fragment crystallizable (Fc) domain that binds to natural killer (NK) cells to induce antibody-dependent cell-mediated cytotoxicity (ADCC).
Importantly, UNLOXCYT (搜索) spares PD-L2 (搜索), which may help preserve immune tolerance in non-tumor tissues such as lung and liver, potentially limiting off-target effects and immune-mediated adverse reactions.
Addressing Significant Unmet Medical Need
CSCC represents the second most common type of skin cancer in the United States, with approximately 1 million people diagnosed annually. While most cases are localized tumors amenable to curative resection, approximately 40,000 cases progress to an advanced stage each year, and approximately 15,000 people die of this disease annually in the United States.
"While there have been advances in aCSCC treatment, there still remains a significant unmet need for therapies that provide durable, long-term efficacy with acceptable tolerability. This is especially important in this aging population who are dealing with significant comorbidities," said Emily Ruiz, MD, MPH, Associate Professor of Dermatology at Harvard Medical School and primary author on the long-term analysis publication.
Clinical Impact and Commercial Launch
Richard Ascroft, CEO of Sun Pharma North America, emphasized the clinical significance of the updated data: "The longer-term results confirm that UNLOXCYT (搜索) represents an advancement in the available treatment options for people living with aCSCC. These pivotal data highlight that more patients responded and maintained their responses to UNLOXCYT for longer than observed in the primary analysis."
UNLOXCYT (搜索) was initially approved by the FDA in 2024, and Sun Pharma intends to commercially launch the drug in early 2026 following this updated label approval. The company will focus on ensuring appropriate patient access while engaging with pathway and guideline groups, including the National Comprehensive Cancer Network (NCCN), to consider this treatment option for future updates.
Dr. David Miller, Co-Director of the NMSC Multi-Disciplinary Clinic at Mass General Brigham Cancer Institute, noted the importance of therapeutic diversity: "Having access to a treatment option that works in a different way than other checkpoint inhibitors can only benefit patients who are fighting this disease and demand an efficacious treatment with acceptable tolerability."
The long-term results from the pivotal study have been published in the Journal of the American Academy of Dermatology (JAAD), further validating the strength of the clinical data. UNLOXCYT (搜索) was recently named a finalist for the 2025 Prix Galien USA Bridges Award, recognizing it as one of the year's most significant biomedical advancements.